CONTEXT: Antiretroviral therapy has been associated with hypercholesterolemia in HIV-infected children. Few longitudinal studies have been conducted to examine this association, however. OBJECTIVE: To evaluate the incidence of and risk factors for development of hypercholesterolemia in a large pediatric study. DESIGN: Prospective cohort study (Pediatric AIDS Clinical Trials Group 219C). PARTICIPANTS: A total of 2122 perinatally HIV-infected children free of hypercholesterolemia at entry. OUTCOME: Development of hypercholesterolemia (total cholesterol >or=220 mg/dL at 2 consecutive visits). Cox proportional hazards models were used to evaluate risk factors. RESULTS: Thirteen percent of children had hypercholesterolemia at entry, and an additional 13% developed hypercholesterolemia during follow-up for an incidence rate of 3.4 cases per 100 person-years (95% confidence interval [CI]: 3.0 to 3.9). After adjustment for age, boosted protease inhibitor (PI) use (hazard ratio [HR] = 13.9, 95% CI: 6.73 to 28.6), nonboosted PI use (HR = 8.65, 95% CI: 4.19 to 17.9), and nonnucleoside reverse transcriptase inhibitor use (HR = 1.33, 95% CI: 1.04 to 1.71) were associated with increased risk of hypercholesterolemia, and higher viral load was protective (>50,000 vs. <or=400 copies/mL; HR = 0.59, 95% CI: 0.39 to 0.90). Self-reported adherent subjects had higher risk. CONCLUSIONS: PIs were significant risk factors for hypercholesterolemia. Higher viral load was protective and may reflect nonadherence. Further follow-up is critical to evaluate long-term consequences of chronic PI exposure and hypercholesterolemia.
CONTEXT: Antiretroviral therapy has been associated with hypercholesterolemia in HIV-infectedchildren. Few longitudinal studies have been conducted to examine this association, however. OBJECTIVE: To evaluate the incidence of and risk factors for development of hypercholesterolemia in a large pediatric study. DESIGN: Prospective cohort study (Pediatric AIDS Clinical Trials Group 219C). PARTICIPANTS: A total of 2122 perinatally HIV-infectedchildren free of hypercholesterolemia at entry. OUTCOME: Development of hypercholesterolemia (total cholesterol >or=220 mg/dL at 2 consecutive visits). Cox proportional hazards models were used to evaluate risk factors. RESULTS: Thirteen percent of children had hypercholesterolemia at entry, and an additional 13% developed hypercholesterolemia during follow-up for an incidence rate of 3.4 cases per 100 person-years (95% confidence interval [CI]: 3.0 to 3.9). After adjustment for age, boosted protease inhibitor (PI) use (hazard ratio [HR] = 13.9, 95% CI: 6.73 to 28.6), nonboosted PI use (HR = 8.65, 95% CI: 4.19 to 17.9), and nonnucleoside reverse transcriptase inhibitor use (HR = 1.33, 95% CI: 1.04 to 1.71) were associated with increased risk of hypercholesterolemia, and higher viral load was protective (>50,000 vs. <or=400 copies/mL; HR = 0.59, 95% CI: 0.39 to 0.90). Self-reported adherent subjects had higher risk. CONCLUSIONS: PIs were significant risk factors for hypercholesterolemia. Higher viral load was protective and may reflect nonadherence. Further follow-up is critical to evaluate long-term consequences of chronic PI exposure and hypercholesterolemia.
Authors: Fortino Solórzano Santos; Laura G Gochicoa Rangel; Gerardo Palacios Saucedo; Guillermo Vázquez Rosales; María Guadalupe Miranda Novales Journal: Arch Med Res Date: 2006-01 Impact factor: 2.235
Authors: Philimon Gona; Russell B Van Dyke; Paige L Williams; Wayne M Dankner; Miriam C Chernoff; Sharon A Nachman; George R Seage Journal: JAMA Date: 2006-07-19 Impact factor: 56.272
Authors: Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Victoria Wirtz; Anna Rightmire; Linda Odeshoo; Colin McLaren Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Tracie L Miller; Gabriel Somarriba; Daniel D Kinnamon; Geoffrey A Weinberg; Lawrence B Friedman; Gwendolyn B Scott Journal: AIDS Res Hum Retroviruses Date: 2010-03 Impact factor: 2.205
Authors: Machline P Paganella; Rachel A Cohen; Donald R Harris; Ricardo de Souza Kuchenbecker; Rosa D Sperhacke; Sergio K Kato; Carmem L Oliveira da Silva; Fernanda T Sturzbecher; Ricardo H S Oliveira; Noris Pavía-Ruz; Rohan Hazra Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Kunjal Patel; Jiajia Wang; Denise L Jacobson; Steven E Lipshultz; David C Landy; Mitchell E Geffner; Linda A Dimeglio; George R Seage; Paige L Williams; Russell B Van Dyke; George K Siberry; William T Shearer; Luciana Young; Gwendolyn B Scott; James D Wilkinson; Stacy D Fisher; Thomas J Starc; Tracie L Miller Journal: Circulation Date: 2013-12-23 Impact factor: 29.690
Authors: Paige L Williams; Rohan Hazra; Russell B Van Dyke; Cenk Yildirim; Marilyn J Crain; George R Seage; Lucy Civitello; Angela Ellis; Laurie Butler; Kenneth Rich Journal: AIDS Date: 2016-01-02 Impact factor: 4.177
Authors: Stacy D Fisher; Thomas J Starc; Vitor Guerra; Paige L Williams; James D Wilkinson; Steven E Lipshultz Journal: Am J Cardiol Date: 2016-01-14 Impact factor: 2.778